

PRODUCT INFORMATION



WT161

Item No. 21099

CAS Registry No.: 1206731-57-8

Formal Name: 8-(hydroxyamino)-8-oxo-octanoic acid, 2-[[4-(diphenylamino)phenyl]methylene]hydrazide

MF: $C_{27}H_{30}N_4O_3$

FW: 458.6


Purity: $\geq 98\%$

UV/Vis.: λ_{max} : 247, 291, 362 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

WT161 is supplied as a crystalline solid. A stock solution may be made by dissolving the WT161 in the solvent of choice, which should be purged with an inert gas. WT161 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of WT161 in these solvents is approximately 10 mg/ml.

WT161 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, WT161 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. WT161 has a solubility of approximately 0.33 mg/ml in a 1:2 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

WT161 is a potent inhibitor of HDAC6 with an IC_{50} value of 0.40 nM.¹ It is selective for HDAC6 over HDAC3 (IC_{50} = 51.61 nM) and induces α -tubulin acetylation, an HDAC6-dependent process, with minimal effect on global lysine acetylation. WT161 inhibits growth of patient-derived multiple myeloma cell lines with IC_{50} values ranging from 1.5 to 4.7 μM . WT161 enhances the cytotoxicity of bortezomib (Item No. 10008822) and carfilzomib (Item No. 17554) against patient-derived multiple myeloma cells. It also decreases tumor size in a human MM.1S multiple myeloma mouse xenograft model when administered in combination with bortezomib at doses of 50 and 0.5 mg/kg, respectively.

Reference

1. Hideshima, T., Qi, J., Paranal, R.M., *et al.* Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. *Proc. Natl. Acad. Sci. USA* **113**(46), 13162-13167 (2016).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/28/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM